Kholoud K. Arafa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kholoud K. Arafa has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Mohammed El-Sherbiny
Center for Materials Science, Zewail City of Science and Technology, Cairo 12588, Egypt
5 shared publications - Ahmed Abdellatif
Department of Biology, School of Sciences and Engineering, The American University in Cairo, Cairo, Egypt
2 shared publications Amr Kordy
Nanomedicine Labs, Center for Materials Science (CMS), Zewail City of Science and Technology, Giza 12578, Egypt
2 shared publications- Amr Hefnawy
Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, TX 78712, USA
1 shared publication - Islam Ahmed Khalil
Department of Pharmaceutics, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University of Science and Technology (MUST), Giza 12582, Egypt
1 shared publication - Marwan Emara
Center for Aging and Associated Diseases, Zewail City of Science, Technology and Innovation, Giza 12578, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (34) , 32898-32907
Actively targeted dendrimer-metal organic framework drug delivery nanoplatform for the treatment of neuroblastoma
Graphical illustration of the developed dendrimer-based nanocarrier for targeted brain cancer therapy. The physicochemical properties of the GSH-functionalized nanocarrier were evaluated, and it's in vitro biological efficacy was assessed.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (34) , 32898-32907
Open AccessActively targeted dendrimer-metal organic framework drug delivery nanoplatform for the treatment of neuroblastoma
Graphical illustration of the developed dendrimer-based nanocarrier for targeted brain cancer therapy. The physicochemical properties of the GSH-functionalized nanocarrier were evaluated, and it's in vitro biological efficacy was assessed.
- 27 August 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (34) , 10648-10661
Actively targeted hyperbranched metal organic framework-based core–shell nanocarriers for the treatment of breast cancer
Illustration of the hyperbranched nanocarrier, depicting the detailed core–shell chemical architecture, the physicochemical characterizations implemented, the intracellular biotargets of the released drug and representative in vivo biological data.
- 27 August 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (34) , 10648-10661
Actively targeted hyperbranched metal organic framework-based core–shell nanocarriers for the treatment of breast cancer
Illustration of the hyperbranched nanocarrier, depicting the detailed core–shell chemical architecture, the physicochemical characterizations implemented, the intracellular biotargets of the released drug and representative in vivo biological data.
- 19 August 2022
- Published by Elsevier
- p. 515-530
Polymeric micelles with cleavable links for drug delivery
- 19 August 2022
- Published by Elsevier
- p. 515-530
Polymeric micelles with cleavable links for drug delivery
- Open Access
- 4 August 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (34) , 21690-21703
Mitochondria-targeted alginate/triphenylphosphonium-grafted-chitosan for treatment of hepatocellular carcinoma
Mitochondrial targeting of anticancer drugs can effectively eradicate tumour cells. TPP+-grafted-chitosan based core–shell nanoparticles were successfully internalized into the mitochondria of HCC cells. Also exhibited antiproliferative activity against liver cancer.
- 4 August 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (34) , 21690-21703
Open AccessMitochondria-targeted alginate/triphenylphosphonium-grafted-chitosan for treatment of hepatocellular carcinoma
Mitochondrial targeting of anticancer drugs can effectively eradicate tumour cells. TPP+-grafted-chitosan based core–shell nanoparticles were successfully internalized into the mitochondria of HCC cells. Also exhibited antiproliferative activity against liver cancer.
- Open Access
- 1 February 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 821-837
Dual-Ligand Functionalized Core-Shell Chitosan-Based Nanocarrier for Hepatocellular Carcinoma-Targeted Drug Delivery
Introduction: Hepatocellular carcinoma represents a major health problem with the related death numbers still increasing. Active targeting is considered an attractive choice for the development of selective therapeutics with limited side effects and improved efficiency. In this study, we report the design, development and evaluation of a novel dual-ligand functionalized core-shell chitosan-based nanocarrier for the selective delivery of doxorubicin (DOX) for treatment of hepatocellular carcinoma (HCC). Methods: Following factorial design experiments, DOX was initially complexed with negatively charged carboxymethyl chitosan-g-poly(acrylate) and then the complex was coated with a positively charged dual-ligand (lactobionic acid and glycyrrhetinic acid)-conjugated chitosan. The developed active targeting system was then tested in vitro on Hep-G2 cells using flow cytometry and fluorescence imaging. Results: The obtained results proved the ability of the dual-ligand system to enhance the intracellular uptake of the drug by 4-fold and 8-fold after 4 hrs and 24 hrs of incubation, respectively. The efficiency of the dual-ligand functionalized nanoparticles was also tested in vivo on Wistar rats with induced liver tumors. Testing of serum biomarkers (albumin, creatinine, urea, alpha fetoprotein, ALT, AST and ALP) in addition to histopathological microscopic examination of liver, kidney and heart tissues confirmed the enhanced safety of the developed targeted nanocarrier system compared to the conventional DOX. Discussion: The developed targeted system showed improved intracellular drug delivery and uptake as well as enhanced safety profile. The nanoparticles were formed based on electrostatic interactions providing the flexibility that allows their use as a model for delivery of other drugs and other targets.
- 1 February 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 821-837
Open AccessDual-Ligand Functionalized Core-Shell Chitosan-Based Nanocarrier for Hepatocellular Carcinoma-Targeted Drug Delivery
Introduction: Hepatocellular carcinoma represents a major health problem with the related death numbers still increasing. Active targeting is considered an attractive choice for the development of selective therapeutics with limited side effects and improved efficiency. In this study, we report the design, development and evaluation of a novel dual-ligand functionalized core-shell chitosan-based nanocarrier for the selective delivery of doxorubicin (DOX) for treatment of hepatocellular carcinoma (HCC). Methods: Following factorial design experiments, DOX was initially complexed with negatively charged carboxymethyl chitosan-g-poly(acrylate) and then the complex was coated with a positively charged dual-ligand (lactobionic acid and glycyrrhetinic acid)-conjugated chitosan. The developed active targeting system was then tested in vitro on Hep-G2 cells using flow cytometry and fluorescence imaging. Results: The obtained results proved the ability of the dual-ligand system to enhance the intracellular uptake of the drug by 4-fold and 8-fold after 4 hrs and 24 hrs of incubation, respectively. The efficiency of the dual-ligand functionalized nanoparticles was also tested in vivo on Wistar rats with induced liver tumors. Testing of serum biomarkers (albumin, creatinine, urea, alpha fetoprotein, ALT, AST and ALP) in addition to histopathological microscopic examination of liver, kidney and heart tissues confirmed the enhanced safety of the developed targeted nanocarrier system compared to the conventional DOX. Discussion: The developed targeted system showed improved intracellular drug delivery and uptake as well as enhanced safety profile. The nanoparticles were formed based on electrostatic interactions providing the flexibility that allows their use as a model for delivery of other drugs and other targets.